• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Drug Trials for Hearing Loss, Tinnitus Therapies Show Promise

by David Bronstein • June 8, 2015

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Gene Therapy Makes a Debut

You Might Also Like

  • Optimal Usage of Intratympanic Drug Therapy for Sudden Hearing Loss Unclear
  • Tinnitus Research Implicates Brain Structures in Hearing Disorder
  • New Drug May Help Prevent, Treat Tinnitus
  • Hearing Loss Less Prevalent among African-Americans
Explore This Issue
June 2015

Dr. Staecker is also the investigational leader of the Novartis-sponsored CGF166 trial, the first to offer gene therapy to adult patients with hearing loss. The protocol was developed by GenVec, a Maryland biotech firm, and involves introducing a gene known as Atoh1 into the inner ear. Atoh1 has been shown in animal models to trigger the formation of inner ear sensory hair cells (PloS One 2014;9:e102077). The hope is that in humans, supporting cells in the inner ear will absorb Atoh1 and transform into functioning hair cells that could mitigate or even reverse hearing loss, Dr. Staecker said.

Although positive anecdotal results have appeared in the lay press, “it’s really too soon to tell” how the four patients who have received the gene therapy at his center ultimately will fare, he said. “We plan on going back to the FDA in the fall with our clinical data, and we anticipate some positive further developments at that time.”

As for the overall direction of otologic drug and gene therapy, Dr. Staecker echoed the importance of pursuing a very focused approach. “Our animal models of tinnitus and hearing loss show that these conditions are extremely heterogeneous and pose very different challenges,” he said. “That’s why we need to develop targeted treatments for different aspects of inner ear disease.”

Disclosure: Dr. Staecker is a member of the surgical advisory board for MedEl Gmbh, and has received grant support from Novartis for animal studies related to gene therapy for inner ear disease.


David Bronstein is a freelance medical journalist based in New Jersey.

Pages: 1 2 3 4 | Single Page

Filed Under: Home Slider, Otology/Neurotology, Practice Focus, Special Report Tagged With: drugs, hearing loss, medication, tinnitusIssue: June 2015

You Might Also Like:

  • Optimal Usage of Intratympanic Drug Therapy for Sudden Hearing Loss Unclear
  • Tinnitus Research Implicates Brain Structures in Hearing Disorder
  • New Drug May Help Prevent, Treat Tinnitus
  • Hearing Loss Less Prevalent among African-Americans

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • 22 Symptoms Common to Patients with Superior Canal Dehiscence Syndrome

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939